STOCK TITAN

Cv Sciences - CVSI STOCK NEWS

Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.

Overview

CV Sciences, Inc. is a comprehensive consumer wellness company that integrates science and nature to improve overall health and well-being. Specializing in nutraceuticals and plant-based foods, the company brings together scientifically-backed hemp extracts and natural ingredients across a diverse range of products. By leveraging deep research, clinical validations, and independent testing, CV Sciences positions itself as an informed and reliable entity in the health and wellness sector.

Core Business and Strategic Focus

The core mission of CV Sciences is to make healthy people healthier. The company’s operations span the development, manufacturing, and distribution of wellness products that cater to both human and pet consumers. Its business model is anchored on the production of hemp-based supplements and plant-derived food products that are sold through multiple channels including direct-to-consumer (B2C) and business-to-business (B2B) outlets. The product portfolio is carefully developed with an emphasis on science and quality, ensuring that each offering is supported by clinical research and complies with industry safety standards.

Product Portfolio and Innovation

CV Sciences offers an expansive range of product lines that exemplify its commitment to innovation and excellence. The +PlusCBD brand, a flagship in hemp extract supplements, has earned recognition for its research-backed approach and quality assurance through clinical studies and laboratory testing. Complementing this is the Cultured Foods brand, which provides a variety of 100% plant-based foods designed to meet the nutritional demands of vegan, gluten-free, and flexitarian consumers. The company has also recently expanded into pet wellness with specialized products designed to support joint health and calming effects for companion animals, an innovation that further extends its market reach.

Quality, Research, and Safety

A major component of CV Sciences' value proposition is its dedication to quality and safety. The company was one of the first to invest in generating scientific evidence required to obtain self-affirmed Generally Recognized as Safe (GRAS) status, particularly for its hemp extract supplements. Clinical research data and published studies support product benefits, ensuring that customers receive products that are not only natural but are scientifically validated for efficacy and safety. Independent laboratory tests and adherence to Good Manufacturing Practices (GMP) further solidify the company’s commitment to producing reliable and high-quality nutraceuticals.

Market Position and Competitive Landscape

Operating in the highly competitive consumer wellness and nutraceutical space, CV Sciences has distinguished itself through its diversified product portfolio and a robust focus on scientific research. Its offerings cater to a range of consumer needs, from natural wellness supplements to innovative pet care products, allowing the company to capture multiple market segments. The breadth of its product lines, combined with strategic measures such as mergers and acquisitions, positions CV Sciences as a resilient and adaptive participant in the natural products market. Detailed market insights and trend analyses reinforce its approach, ensuring that the company maintains a competitive edge in a rapidly evolving industry.

Global Presence and Operational Excellence

With primary offices and facilities strategically located in San Diego, California, and Warsaw, Poland, CV Sciences leverages a global operational framework to optimize production and distribution channels. The company’s strategic acquisitions, including Elevated Softgels and Extract Labs, enhance its manufacturing capabilities while providing operational flexibility and cost efficiencies. This global footprint underpins its long-standing commitment to excellence, ensuring consistent quality and timely delivery of state-of-the-art wellness products to customers worldwide.

Strategic Acquisitions and Integration

The proactive pursuit of strategic acquisitions bolsters CV Sciences’ operational capacity and enriches its product innovation pipeline. By integrating companies with complementary technologies and manufacturing strengths, such as Elevated Softgels and Extract Labs, the firm has expanded its ability to produce cost-effective and high-quality encapsulated supplements and tinctures. These acquisitions not only streamline the supply chain but also provide synergistic benefits that translate into enhanced market responsiveness and broader product offerings.

Commitment to Science and Consumer Wellness

At its core, CV Sciences is driven by a mission that combines scientific rigor with natural wellness. Every segment of its operation is designed to uphold the values of transparency, quality, and reliability. Whether through the development of hemp extract-based solutions, the diversification into cannabinoid-free wellness products under the +PlusHLTH brand, or the careful formulation of pet care products, the company consistently demonstrates its dedication to consumer well-being. This scientifically-oriented approach, coupled with a commitment to continuous innovation, underscores the company’s role as an authoritative source in the wellness industry.

In summary, CV Sciences offers a well-rounded, research-informed perspective on modern health and nutrition by providing a diverse array of nutraceutical and plant-based foods. Its strategic emphasis on scientific validation and operational excellence makes it a noteworthy name for anyone seeking comprehensive and quality-driven wellness solutions.

Rhea-AI Summary

CV Sciences (OTCQB:CVSI) announced it will release its second-quarter financial results on August 12, 2021, after market close. A conference call for investors is scheduled the same day at 1:30 PM PT. The call will be accessible via the company's Investor Relations webpage and will be archived for 30 days. CV Sciences operates two divisions: a consumer product segment focused on CBD products and a drug development segment for CBD-based therapeutics. Its PlusCBD™ brand is recognized as a leader in the natural products market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
none
-
Rhea-AI Summary

CV Sciences, Inc. (OTCQB:CVSI) announced that its CV™ Defense product received the 2021 Product of the Year: Immune Support Award from NutraIngredients-USA. This award recognizes innovation in nutrition and dietary supplements. CV™ Defense contains ingredients like PEA, reishi mushroom extract, vitamins A and D, selenium, and zinc, aimed at enhancing immune health. The award underscores the company's commitment to expanding its product portfolio beyond CBD, reflecting strong initial sales and consumer demand for effective wellness products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

CV Sciences announced progress in developing a CBD-based pharmaceutical for nicotine addiction in collaboration with UC San Diego. A preclinical study revealed that chronic CBD treatment significantly reduced withdrawal symptoms in nicotine-dependent rats. This research highlights CV Sciences' commitment to addressing the $2 billion smokeless tobacco addiction market, with potential FDA-approved treatment in development. The company has secured a patent for a proprietary CBD and nicotine formulation, further expanding its product development opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

CV Sciences (CVSI) reported Q1 2021 revenue of $4.8 million, a 41% decrease from $8.3 million in Q1 2020, attributed to the ongoing COVID-19 pandemic and increased market competition. Despite this, the gross margin slightly improved to 48.7% from 48.5% year-over-year. The company’s cash balance rose to $5.7 million, up from $4.5 million at year-end. Retail distribution expanded to over 7,300 stores, up from 5,799 a year prior. New product launches, including ProCBD™ and PlusCBD™ Calm and Sleep gummies, were well received, indicating potential future growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
-
Rhea-AI Summary

CV Sciences has launched new PlusCBD™ Calm and Sleep gummies aimed at supporting healthy stress responses and sleep cycles. Each gummy contains 10mg of CBD, plus 5-HTP and L-Theanine for Calm, and melatonin, magnolia bark, and lemon balm for Sleep. These products promise no artificial additives and are third-party tested for quality. CV Sciences emphasizes its commitment to scientifically formulated products backed by clinical research, available for purchase online and in retail later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

CV Sciences (OTCQB:CVSI) will announce its financial results for Q1 2021 on May 13, 2021, after market close. A conference call to discuss these results is scheduled for 1:30 PM PT (4:30 PM ET) on the same day. Access to the call will be available through the Company’s Investor Relations webpage, with a replay offered two hours post-call until May 20, 2021. CV Sciences operates in two sectors: consumer products and drug development, with its PlusCBD™ products leading the hemp-derived CBD market across over 7,300 retail locations in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
Rhea-AI Summary

CV Sciences (OTCQB: CVSI) has announced a partnership with Alkemist Labs to support the National Institute of Standards and Technology (NIST) in enhancing cannabis testing methodologies. This collaboration aims to improve measurement accuracy for cannabis products, crucial for legal and safety claims. CV Sciences will provide hemp oil samples for testing, and Alkemist Labs will measure cannabinoid levels. NIST’s Canna Quality Assurance Program (CannaQAP) will benefit various laboratories and researchers in the cannabis industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary

CV Sciences reported financial results for the year ended December 31, 2020, with revenues of $24.4 million, a 55% decline from $53.7 million in 2019. The gross margin stood at 45.1%, while the cash balance remained stable at $4.5 million. The company expanded its retail distribution to over 7,300 stores, up from 5,500 the previous year. Despite these advancements, an operating loss of $22.6 million was reported, marking an increase from $17.2 million in 2019, and a negative adjusted EBITDA of $11.6 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
-
Rhea-AI Summary

CV Sciences, Inc. (OTCQB:CVSI) will release its financial results for the fiscal year and fourth quarter ending December 31, 2020, on March 18, 2021. The company will conduct a conference call on the same day at 1:30 p.m. PT, which can be accessed via the Investor Relations section of its website. The PlusCBD™ brand leads the hemp-derived CBD market in over 7,300 retail locations and is compliant with Good Manufacturing Practices (GMP). The company emphasizes its commitment to scientific research in support of its products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
Rhea-AI Summary

CV Sciences has announced a major refresh of its PlusCBD™ product line, introducing over 30 new products in the next 45 days. The updated line features contemporary packaging and innovative products such as extra strength gummies and softgels. Each product now includes a QR code linking to lab reports, ensuring quality assurance. According to CEO Joseph Dowling, extensive market research led to this redesign aimed at broadening consumer appeal and reinforcing brand equity. PlusCBD™ remains the top-selling CBD brand, derived from sustainable U.S. and EU hemp.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Cv Sciences (CVSI)?

The current stock price of Cv Sciences (CVSI) is $0.0302 as of April 4, 2025.

What is the market cap of Cv Sciences (CVSI)?

The market cap of Cv Sciences (CVSI) is approximately 5.7M.

What core business does CV Sciences focus on?

CV Sciences specializes in consumer wellness products by integrating science and natural ingredients. Its operations include the development and distribution of hemp extract supplements, plant-based foods, and pet wellness products.

How does CV Sciences ensure product quality and safety?

The company adheres to stringent quality standards including GMP-certification and independent laboratory testing. Its products are supported by clinical research and published studies, ensuring safety and efficacy.

What distinguishes the +PlusCBD brand?

The +PlusCBD brand is known for its science-backed approach, clinical research support, and self-affirmed GRAS status. It is recognized as a top-selling hemp extract supplement within the natural products market.

What role do strategic acquisitions play in CV Sciences' growth?

Strategic acquisitions like Elevated Softgels and Extract Labs enhance the company’s manufacturing capabilities and operational flexibility. These moves allow CV Sciences to in-source production and expand its product portfolio cost-effectively.

How does CV Sciences cater to the pet wellness market?

CV Sciences has developed specialized pet products, such as CBD-infused chews for joint and calming health, which are supported by rigorous research and validated by safety studies. These offerings extend the company’s commitment to consumer well-being to pet care.

What is CV Sciences' approach to innovation?

Innovation at CV Sciences is driven by a commitment to scientific research and the integration of natural ingredients. The company continuously develops new products and explores strategic opportunities to enhance its portfolio and market reach.

Which sales channels does CV Sciences use to reach its customers?

CV Sciences employs a diverse sales strategy that includes both B2B and B2C channels. This allows the company to effectively distribute its wellness products through selected retail locations as well as direct consumer platforms.

How does the company maintain its global operational efficiency?

With key facilities in San Diego and Warsaw, CV Sciences leverages a global operational framework. Strategic acquisitions and a focus on manufacturing excellence ensure that the company maintains high standards in production and distribution.
Cv Sciences

OTC:CVSI

CVSI Rankings

CVSI Stock Data

5.71M
184.23M
0.02%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
San Diego